Professor Filippo Drago | |
---|---|
![]() | |
Born | Filippo Drago 5 December 1954 Italy |
Alma mater | University of Catania [1] Utrecht University [1] |
Scientific career | |
Institutions | University of Szeged [1] Weizmann Institute of Science [1] University of North Carolina at Chapel Hill [1] University of Catania |
Thesis | Prolactin and Behavior [1] (1982) |
Doctoral advisor | David de Wied [2] |
Filippo Drago (born 5 December 1954 in Enna, Italy) is an Italian pharmacologist, neurologist and psychiatrist. [2]
He is a professor of pharmacology at the University of Catania, Italy. [1]
Filippo Drago has several patents in the field of pharmacology and is author of more than 500 papers published in peer-reviewed journals. [3] [4]
Additionally, Filippo Drago is a certified Italian freelance journalist. [5]
Filippo Drago obtained his medical degree in 1978 at the University of Catania, Italy, and obtained a PhD in pharmacology in 1982 at the University of Utrecht, in the Netherlands, working with David de Wied. [2]
Afterwards, he worked at the University of Szeged in Hungary, the Weizmann Institute of Science in Israel, and the Department of Psychiatry of University of North Carolina at Chapel Hill, USA. [1]
From 2004 to 2010, he was a member of the Scientific Board of the Italian public agency for drug evaluation, the "Agenzia Italiana del Farmaco" (AIFA). [2] [6] In 2012, he was also appointed as a member of the board for pricing and reimbursement of the same agency. [7]
At the University of Catania, he was, among other roles, the Director of the International PhD Program in Neuropharmacology (2002–2013) and he is the coordinator of the master's degree in drug regulatory affairs. [8] [1] He is also a professor of Pharmacology and, since 2014, the Director of the Department of Biomedical and Biotechnological Sciences. [1]
From 2012 to 2014, Drago was President of the Federation of European Pharmacological Societies (EPHAR). [2] He is currently the President of the Italian branch of the Association for Research in Vision and Ophthalmology (ARVO), IT-ARVO, and the Association for Ocular Pharmacology and Therapeutics (AOPT), an organization that welcomes members from disciplines related to ocular pharmacology and its therapeutic applications. [9] [10]
In June 2019, as part of the "Università Bandita" investigation conducted by the Catania Public Prosecutor's Office, he – together with other eight professors and the Dean of the University of Catania – was investigated for having influenced the outcome of public competitions for the assignment of positions within the University of Catania. As a result, he was temporarily suspended from his role as Professor, pending the outcome of the judicial proceedings. [11]
He was fully readmitted as Professor in October 2019, when he was elected President of the CERD (Center for Research and Consultation on HTA and Drugs Regulatory Affairs) of the University of Catania. [12]
In 2020, Filippo Drago was appointed as chairman of the International Advisory Council within the Human Health Education and Research Foundation (HHERF). [13]
In 2014, Drago was awarded the Order for the International Merit of Blood by the International Federation of Blood Donor Organizations. [14] In the same year, he was also awarded the "ARVO Silver Fellow", an honour conferred to ARVO members "for their individual accomplishments, leadership and contributions to the Association". [15] [16]
In 2014, Drago was among the recipients of the "Rodolfo Paoletti Medal", which was established to "honour distinguished pharmacologists who have achieved merits for the discipline of pharmacology in Europe". [17]
In 2021, Filippo Drago became an "ARVO Golden Fellow" for his commitment "to advance research worldwide into understanding the visual system and preventing, treating and curing its disorders”. [18] [19]
Filippo Drago is married and has four children. [1]
Vision science is the scientific study of visual perception. Researchers in vision science can be called vision scientists, especially if their research spans some of the science's many disciplines.
Fight for Sight is a nonprofit organization in the United States which funds medical research in vision and ophthalmology. It was formed in 1946 as the National Council to Combat Blindness (NCCB), the first non-profit organization in the United States to fund vision research; 2011 marked its 65th anniversary.
Dr. George Spaeth is an American ophthalmologist specializing in glaucoma at Wills Eye Institute. Spaeth is also affiliated with Thomas Jefferson University Hospital, Graduate Hospital of the University of Pennsylvania, Chestnut Hill Hospital, Bryn Mawr Hospital, and Miner's Memorial Hospital.
Julia A. Haller is an American ophthalmologist who is a Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University. She also holds the William Tasman, M.D. Endowed Chair at Wills Eye Hospital in Philadelphia, where she is Ophthalmologist-in-Chief.
The Federation of European Pharmacological Societies (EPHAR) is a non-profit voluntary association established to advance research and education in the science of pharmacology and to promote co-operation between national/regional pharmacological societies in Europe and surrounding countries. It is an umbrella organization of currently 27 national societies for pharmacology and represents over 10,000 individual pharmacologists in Europe. Moreover it seeks to co-operate with other international organizations, especially the International Union of Basic and Clinical Pharmacology (IUPHAR) of which EPHAR is an associate member.
Martin Jeffrey Steinbach was an American vision researcher who spent most of his career in Canada. He was Distinguished Research Professor Emeritus in the Department of Psychology at York University. He received a master's degree from Connecticut College in 1965 and a Ph.D. from Massachusetts Institute of Technology (MIT) in 1968.
The Association for Ocular Pharmacology and Therapeutics (AOPT) is an organization that welcomes members from disciplines related to ocular pharmacology and its therapeutic applications. The mission of AOPT is the sustenance of a scientific network aiming the dissemination of knowledge in the field of ocular disease, pharmacology and therapeutics.
Reza Dana is the Claes H. Dohlman Professor of Ophthalmology, senior scientist and W. Clement Stone Clinical Research Scholar at Massachusetts Eye and Ear, Harvard Medical School, and director of the Harvard-Vision Clinical Scientist Development Program.
Michael David Abràmoff is a Dutch-American ophthalmologist, computer scientist and entrepreneur. He is the Robert C. Watzke Professor of Ophthalmology and Visual Sciences at the Roy J. and Lucille A. Carver College of Medicine at the University of Iowa. He is the Founder and Executive Chairman of Digital Diagnostics, of Iowa City, called by Wired Magazine "the bolder AI company", and which received the first FDA marketing authorization for an autonomous diagnostic AI system in any field of medicine.
Joan Whitten Miller is a Canadian-American ophthalmologist and scientist who has made notable contributions to the treatment and understanding of eye disorders. She is credited for developing photodynamic therapy (PDT) with verteporfin (Visudyne), the first pharmacologic therapy for retinal disease. She also co-discovered the role of vascular endothelial growth factor (VEGF) in eye disease and demonstrated the therapeutic potential of VEGF inhibitors, forming the scientific basis of anti-VEGF therapy for age-related macular degeneration (AMD), diabetic retinopathy, and related conditions.
Maria Pia Abbracchio is an Italian pharmacologist who researches the biochemical effect of drugs at the cellular level. She has conducted research all over the world and is one of the scientists Thomson Reuters has named as most cited scientists since 2006. She is known for her work with purinergic receptors and identification of GPR17. In 2014 she was awarded the Order of Merit of the Italian Republic for her individual scientific accomplishments.
Silvio Garattini is an Italian scientist, pharmacology research scientist, physician and professor in chemotherapy and pharmacology and director of the Mario Negri Institute for Pharmacological Research.
John E. Dowling is an American neuroscientist and Gordon and Llura Gund Research Professor of Neurosciences at Harvard University. He is best known for his seminal work in vision science, having elucidated the biochemistry of rhodopsin and development of the vertebrate retina, as well as diseases that affect vision such as vitamin A deficiency and retinitis pigmentosa. He was elected to the American Academy of Arts and Sciences in 1972, the National Academy of Sciences in 1976, and the American Philosophical Society in 1992.
Patricia Ann D'Amore is a professor at Harvard Medical School, where she is the Charles L. Schepens Professor of Ophthalmology, and Professor of Pathology.
Dimitri Azar M.D. is an American ophthalmologist, professor, and businessman who leads Twenty Twenty Therapeutics, a joint venture established by Santen and Verily. Dr. Azar has held roles at Novartis and Verily, Alphabet's Life sciences research organization. He served as dean of the College of Medicine at the University of Illinois at Chicago (UIC) from 2011 to 2018.
Steven J. Fliesler is an American biochemist and cell biologist, whose research has focused on how lipid metabolism supports the normal structure and function of the vertebrate retina. He currently is the Meyer H. Riwchun Endowed Chair Professor of Ophthalmology and Vice-Chair/Director of Research in the Department of Ophthalmology, Jacobs School of Medicine and Biomedical Sciences, at the University at Buffalo, The State University of New York. In 2014, he became a UB Distinguished Professor, and in 2018 was promoted to the rank of SUNY Distinguished Professor. He is the author or coauthor of more than 150 publications, including peer-reviewed scientific/biomedical journal articles, books and book chapters.
The Association for Research in Vision and Ophthalmology is an American learned society dedicated to ophthalmology and other vision-related topics. As of 2019, it has almost 12,000 members from 75 different countries. It was established in Washington, D.C., in 1928 as the Association for Research in Ophthalmology. In May 1970, it was renamed to its current name to reflect its broader scope. It is based in Rockville, Maryland. It publishes three academic journals: Investigative Ophthalmology & Visual Science, the Journal of Vision, and Translational Vision Science & Technology.
Gaetano Giorgio Gemmellaro was an Italian geologist, paleontologist and politician.
Alon Harris, MS, PhD, FARVO is an internationally-active clinical scientist, professor of ophthalmology, educator, inventor and researcher in the field of ocular blood flow and its relationship to diseases of the eye. Harris served as the principal or co-principal investigator on more than 60 research grants, published more than 368 peer-reviewed articles, and wrote 22 books and 69 book chapters. As of 2021, he holds two patents. Harris sits on the Board of Directors of The Glaucoma Foundation and is the Vice Chair of International Research and Academic Affairs and Director of the Ophthalmic Vascular Diagnostic and Research Program at Icahn School of Medicine at Mount Sinai.
Alfredo Arrigo Sadun is an American ophthalmologist, academic, author and researcher. He holds the Flora L. Thornton Endowed Chair at Doheny Eye Centers-UCLA and is Vice-Chair of Ophthalmology at UCLA.
{{cite web}}
: CS1 maint: url-status (link)